Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

Phase 1/2 Unknown 18 enrolled Scandion Oncology A/S Alcedis GmbH · collab

NaSingle-groupOpen-labelTreatment

Summary

An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.

Timeline

Start: 2020-10-27
Primary completion: 2022-03-30
Completion: 2022-05-15

Publications

Shim S, Reinacher-Schick A, Kraeft AL, Per Pfeiffer, Tarpgaard LS, Ettrich TJ, Kestler A, Christensen S, Jandu H, Nawabi M, Roest NL, Damstrup L, Vestlev PM, Brunner N, Stenvang J, Ladekarl M. PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer. Invest New Drugs. 2025 Apr;43(2):337-347. doi: 10.1007/s10637-025-01526-7. Epub 2025 Apr 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EMIDURDAR	Small molecule	150 mg	Oral
Subject	EMIDURDAR	Small molecule	200 mg	Oral
Subject	EMIDURDAR	Small molecule	250 mg	Oral
Subject	EMIDURDAR	Small molecule	300 mg	Oral
Subject	EMIDURDAR	Small molecule	350 mg	Oral
Background	Gemcitabine	Small molecule	—	—
Background	Nab-paclitaxel	Small molecule	—	—

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

Summary

Timeline

Publications

Drugs

Indications